Cite
HARVARD Citation
Sadeghi, S. et al. (n.d.). Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038). European journal of cancer. pp. S197-. [Online].